Rho Executive and Leadership Team

Lawrence Morentz, the Chief Executive Officer at Rho, directs the overarching strategic vision for the organization. By aligning clinical research capabilities with the evolving needs of the pharmaceutical industry, Morentz ensures the company maintains a competitive edge in drug development. This leadership role involves constant engagement with the Board to refine long-term growth objectives and market positioning. Overseeing the entire corporate structure, the Chief Executive Officer fosters a culture of scientific excellence and operational integrity. Lawrence Morentz drives the expansion of service offerings to meet complex global regulatory requirements. Through rigorous oversight of organizational performance, Morentz secures the stability necessary for sustained innovation. The Chief Executive Officer prioritizes the delivery of high-quality data to clients, ultimately supporting the successful transition of new therapies from early-stage research to commercial availability across diverse international markets.

Francis Wall, the Chief Financial Officer at Rho, manages the fiscal health and capital allocation strategies for the organization. By optimizing financial planning and analysis, Wall supports the resource-intensive nature of clinical research operations. This leadership role involves maintaining robust internal controls and ensuring compliance with complex financial regulations. Overseeing the financial reporting processes, the Chief Financial Officer provides the transparency required for informed decision-making by the executive team. Francis Wall directs the budgeting initiatives that fuel investment in advanced research technologies and infrastructure. Through careful management of corporate assets, Wall strengthens the financial foundation of the company. The Chief Financial Officer collaborates with other leaders to align fiscal performance with the broader mission of accelerating drug development. Ultimately, Wall ensures the long-term economic viability of the firm while supporting the scaling of clinical services across North American and global markets.

Alena Hammond, the Chief Operating Officer at Rho, executes the daily operational strategies that drive clinical trial efficiency. By streamlining project management workflows, Hammond ensures that research services meet strict timelines and quality standards. This leadership role involves coordinating cross-functional teams to deliver seamless support throughout the drug development lifecycle. Overseeing the execution of complex clinical protocols, the Chief Operating Officer maintains operational excellence across all research sites. Alena Hammond directs the implementation of standardized processes that enhance productivity and reduce cycle times for pharmaceutical clients. Through continuous improvement initiatives, Hammond optimizes resource utilization and operational capacity. The Chief Operating Officer works closely with the executive team to scale service delivery in response to increasing market demand. Ultimately, Hammond ensures that the operational infrastructure remains agile and capable of supporting diverse therapeutic areas within the global clinical research landscape.

Deborah Johnson, the President at Rho, leads the execution of corporate initiatives and oversees the integration of business functions. By fostering collaboration across departments, Johnson ensures that the company's strategic goals translate into tangible results for clients. This leadership role involves managing the day-to-day business activities that sustain the firm's market presence. Overseeing the alignment of service delivery with client expectations, the President maintains high levels of satisfaction and project success. Deborah Johnson directs the implementation of corporate policies that promote efficiency and professional excellence. Through active engagement with the leadership team, Johnson drives the pursuit of new business opportunities and the expansion of service capabilities. The President focuses on maintaining the company's reputation for quality and reliability in the clinical research industry. Ultimately, Johnson ensures that the organization remains focused on its core mission of supporting drug development through disciplined management and strategic foresight.

Biljana Djordjevic, the Technology Chief of Staff at Rho, architects the digital transformation strategies that modernize clinical research data management. By integrating advanced software solutions, Djordjevic enhances the accuracy and accessibility of trial information for research teams. This leadership role involves bridging the gap between technical capabilities and clinical operational requirements. Overseeing the deployment of secure data platforms, the Technology Chief of Staff ensures compliance with stringent industry standards for information protection. Biljana Djordjevic directs the adoption of innovative tools that automate manual processes and improve overall research throughput. Through strategic technology planning, Djordjevic supports the company's ability to handle complex data sets with precision. The Technology Chief of Staff collaborates with other executives to align digital initiatives with the firm's long-term research goals. Ultimately, Djordjevic drives the technological advancements necessary to maintain a leading position in the competitive clinical research services sector.

Andrew Feigin, the Chief Medical Officer at Rho, provides the scientific and clinical expertise necessary to guide complex drug development programs. By overseeing medical monitoring and safety surveillance, Feigin ensures the highest standards of patient welfare throughout clinical trials. This leadership role involves interpreting intricate medical data to inform strategic decisions for pharmaceutical partners. Overseeing the medical affairs department, the Chief Medical Officer maintains rigorous scientific integrity across all research projects. Andrew Feigin directs the development of clinical protocols that address specific therapeutic challenges and regulatory expectations. Through expert guidance, Feigin supports the successful navigation of the drug approval process. The Chief Medical Officer collaborates with the executive team to ensure that clinical strategies remain grounded in current medical knowledge and best practices. Ultimately, Feigin drives the scientific quality of the company's research services, ensuring that every trial contributes meaningfully to the advancement of new medical therapies.